Home › Companies › IONIS PHARMACEUTICALS INC. › 2023-2024

IONIS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and IONIS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
408Asset managers
2,097Fund votes
June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 5 items on IONIS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024: 2 elected · 3 approved.

Material dissent

3. Approval of an amendment of the Ionis Pharmaceuticals, Inc 78% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IONIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by IONIS PHARMACEUTICALS INC.

These tallies are IONIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IONIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Brett P. Monia	120,462,201	2,850,850	157,065	--	10,132,983	98%	Elected	—
Elect Director: Michael Yang	109,136,314	14,191,316	142,486	--	10,132,983	88%	Elected	—
2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed	118,899,475	4,228,901	341,740	--	10,132,983	97%	Approved	—
3. Approval of an amendment of the Ionis Pharmaceuticals, Inc	96,453,407	26,912,642	104,067	--	10,132,983	78%	Approved	—
4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year	129,900,428	3,455,435	247,236	--	0	97%	Approved	—

This meeting is also recorded here as June 7, 2024; both records come from the same filing, so the date should be checked against it.

Source: IONIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.

How asset managers voted at the IONIS PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 408 asset managers that disclosed a IONIS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Brett P. Monia

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 120,462,201AGAINST: 2,850,850

Details: description as filed, official tally, votes by 101 asset managers

Description as filed by funds: Election of Directors: Brett P. Monia

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Brett P. Monia”): 120,462,201 for, 2,850,850 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2027 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 101 asset managers below reported 61,455,312 for, 161,530 against, 635 abstained.

FOR

FOR: 61,455,312AGAINST: 161,530ABSTAIN: 635

Largest asset managers voting on “Election of Directors: Brett P. Monia” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	13,218,521	0	For
T. Rowe Price	10,283,039	0	For
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,477,809	6,071	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	849,000	116,716	Mixed
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	630,000	0	For
TIAA	387,417	0	For
John Hancock	293,466	0	For
Empower	285,377	0	For
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	219,421	0	For
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	130,027	0	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

2. Elect Director: Michael Yang

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%

FOR: 109,136,314AGAINST: 14,191,316

Details: description as filed, official tally, votes by 101 asset managers

Description as filed by funds: Election of Directors: Michael Yang

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael Yang”): 109,136,314 for, 14,191,316 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2027 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 101 asset managers below reported 52,161,258 for, 9,455,585 against, 635 abstained.

FORAGAINST

FOR: 52,161,258AGAINST: 9,455,585ABSTAIN: 635

Largest asset managers voting on “Election of Directors: Michael Yang” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	13,218,521	0	For
T. Rowe Price	2,687,377	7,595,662	Mixed
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,483,880	0	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	116,716	849,000	Mixed
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	0	630,000	Against
TIAA	387,417	0	For
John Hancock	281,280	12,186	For
Empower	12,077	273,300	Against
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	219,421	0	For
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	73,127	56,900	Mixed
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

3. 3. Approval of an amendment of the Ionis Pharmaceuticals, Inc

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

78% Approved · of votes cast

FOR 78%AGAINST

FOR: 96,453,407AGAINST: 26,912,642

Details: description as filed, official tally, votes by 101 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER SUCH PLAN BY 3,300,000 SHARES TO AN AGGREGATE OF 38,500,000 SHARES AND TO PROHIBIT CERTAIN SHARE RECYCLING ON FULL VALUE AWARDS.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval of an amendment of the Ionis Pharmaceuticals, Inc”): 96,453,407 for, 26,912,642 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 101 asset managers below reported 47,546,009 for, 14,024,680 against.

FORAGAINST

FOR: 47,546,009AGAINST: 14,024,680

Largest asset managers voting on “TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGAT” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	2,220,781	10,997,740	Mixed
T. Rowe Price	10,283,039	0	For
TWEEDY, BROWNE FUND INC.	0	2,954,743	Against
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,483,221	659	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	965,716	0	For
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	630,000	0	For
TIAA	387,417	0	For
John Hancock	293,466	0	For
Empower	285,377	0	For
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	219,421	0	For
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	130,027	0	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.

4. 2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 118,899,475AGAINST: 4,228,901

Details: description as filed, official tally, votes by 407 asset managers

Description as filed by funds: To make an advisory vote on executive compensation.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of th”): 118,899,475 for, 4,228,901 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 98 asset managers voting on “To make an advisory vote on executive compensation.” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	13,218,521	0	For
T. Rowe Price	10,283,039	0	For
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,480,344	3,536	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	965,716	0	For
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	630,000	0	For
Artisan	563,948	0	For
TIAA	387,417	0	For
John Hancock	293,466	0	For
Empower	285,377	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	219,421	0	For
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	130,027	0	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Fund voting reports, all 98 managers: 61,796,268 for, 78,046 against, 1 withheld, 11,636 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 336 asset managers voting on “To make an advisory vote on executive compensation.” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	20,487,244	0	For
T. Rowe Price	16,392,356	0	For
Wellington	5,419,781	0	For
Clearbridge Investments, LLC	4,353,081	0	For
BlackRock	3,526,251	14,620	For
Tweedy, Browne Co LLC	3,454,676	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	3,092,500	0	For
State Street	3,044,723	3,931	For
PICTET ASSET MANAGEMENT SA	2,647,321	0	For
BVF INC/IL	2,428,613	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,308,078	0	For
ORBIMED ADVISORS LLC	2,013,033	0	For
Deep Track Capital, LP	1,492,451	0	For
Charles Schwab	1,301,673	0	For
Candriam S.C.A.	0	908,486	Against
Capital Group	839,484	125	For
Man Group plc	824,080	0	For
BNP Paribas Asset Management Holding S.A.	0	733,334	Against
Invesco	718,852	0	For
Two Sigma	639,391	0	For
Point72	566,735	0	For
JPMorgan	552,748	0	For
Northern Trust	448,560	100	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	446,603	0	For
Nuveen	398,585	0	For

Institutional-manager reports, all 336 managers: 85,703,246 for, 3,087,928 against, 247 withheld, 78,404 abstained, 519 not voted, 4 unknown. Showing the 25 largest; see all in the interactive database.

5. 4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 129,900,428AGAINST: 3,455,435

Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2024 FISCAL YEAR.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year”): 129,900,428 for, 3,455,435 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).

The 102 asset managers below reported 61,365,161 for, 240,780 against, 1 withheld, 11,636 abstained.

FOR

FOR: 61,365,161AGAINST: 240,780ABSTAIN: 11,636WITHHOLD: 1

Largest asset managers voting on “TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2024 FISCAL YEA” at IONIS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	17,601,975	0	For
Fidelity	13,218,521	0	For
T. Rowe Price	10,283,039	0	For
TWEEDY, BROWNE FUND INC.	2,954,743	0	For
Waddell & Reed	2,335,501	0	For
BlackRock	2,153,397	0	For
Legg Mason	1,726,610	0	For
State Street	1,481,345	2,535	For
ARK ETF Trust	1,385,268	0	For
Charles Schwab	1,295,535	0	For
Jackson National	965,716	0	For
Capital Group	839,463	0	For
Invesco	648,901	0	For
MassMutual	630,000	0	For
TIAA	387,417	0	For
John Hancock	293,466	0	For
Empower	285,377	0	For
Artisan	243,854	0	For
Ivy Variable Insurance Portfolios	231,201	0	For
Aberdeen	0	219,421	Against
Delaware/Macquarie	215,677	0	For
Pacific Life	184,654	0	For
Northwestern Mutual	130,027	0	For
PIONEER SERIES TRUST XII	123,156	0	For
Hartford	123,041	0	For

Showing the 25 largest of 102 asset managers. See all 102 in the interactive database.

Largest IONIS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 145,844,719 shares outstanding at the time of that meeting.

Fund voting reports: top IONIS PHARMACEUTICALS INC. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	12.07%
2	Fidelity	9.06%
3	T. Rowe Price	7.05%
4	TWEEDY, BROWNE FUND INC.	2.03%
5	Waddell & Reed	1.60%
6	BlackRock	1.48%
7	Legg Mason	1.18%
8	State Street	1.02%
9	ARK ETF Trust	0.95%
10	Charles Schwab	0.89%

Institutional-manager reports: top IONIS PHARMACEUTICALS INC. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Fidelity	14.05%
2	T. Rowe Price	11.24%
3	Wellington	3.72%
4	Clearbridge Investments, LLC	2.98%
5	BlackRock	2.43%
6	Tweedy, Browne Co LLC	2.37%
7	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	2.12%
8	State Street	2.09%
9	PICTET ASSET MANAGEMENT SA	1.82%
10	BVF INC/IL	1.67%

Reported IONIS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

IONIS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	16.24%	13F
FMR LLC	14.76%	DEF14A
Vanguard Group	11.30%	13F
BlackRock	7.16%	13F
Black Rock, Inc.	6.21%	DEF14A
State Street	2.85%	13F
T. Rowe Price	2.42%	13F
Geode Capital	1.62%	13F
Charles Schwab	0.89%	13F
Morgan Stanley	0.81%	13F

Percentages above are of 145,844,719 shares outstanding, as reported by IONIS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IONIS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At IONIS PHARMACEUTICALS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 408 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,097 separate fund positions. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — IONIS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: IONIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.

IONIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.